Glaukos Corporation (GKOS)
NYSE: GKOS
· Real-Time Price · USD
85.61
0.29 (0.34%)
At close: Oct 15, 2025, 3:59 PM
85.60
-0.01%
After-hours: Oct 15, 2025, 04:10 PM EDT
0.34% (1D)
| Bid | 85.26 |
| Market Cap | 4.91B |
| Revenue (ttm) | 432.95M |
| Net Income (ttm) | -92.79M |
| EPS (ttm) | -1.61 |
| PE Ratio (ttm) | -53.17 |
| Forward PE | n/a |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 85.82 |
| Volume | 640,648 |
| Avg. Volume (20D) | 924,017 |
| Open | 85.74 |
| Previous Close | 85.32 |
| Day's Range | 83.29 - 86.37 |
| 52-Week Range | 77.10 - 163.71 |
| Beta | 0.76 |
| Ex-Dividend Date | n/a |
About GKOS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GKOS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GKOS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsGlaukos Corporation is scheduled to release its earnings on
Oct 29, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-8.46%
Glaukos shares are trading lower. The company repo...
Unlock content with
Pro Subscription
5 months ago
-11.36%
Glaukos shares are trading lower after the company reported Q1 financial results. Additionally, Needham cut its price target on the stock from $176 to $115.
2 months ago · businesswire.com
Glaukos Announces Participation in Wells Fargo Healthcare ConferenceALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
